Table 2 Effect of tachykinin receptors antagonism on asthma outcomes
From: Tachykinin receptors antagonism for asthma: a systematic review
Control | Treated | ||||
|---|---|---|---|---|---|
Outcome | N | Mean(SD) | N | Mean(SD) | p |
• AIRWAY RESPONSIVENESS: | |||||
Log PC 35 sGaw NKA mol/ml | |||||
FK224 (NK-1R/NK-2R antagonist) | 10 | -6.04(0.18) | 10 | -6.19(0.23) | n.s. |
Joos et al, 1996 | |||||
PC 20 -AMP mg/ml | |||||
SR 48968C (NK-1R/NK2R antagonist) | |||||
Kraan et al, 2001 | 12 | 1.46(1.11) | 6 | 1.25(0.98) | n.s. |
Log 10 PC 20 -NKA mol/ml | |||||
MEN 11420 (NK-2R antagonist) | |||||
Shelfhout et al, 2009 | 12 | -6.38(0.26) | 12 | -6.92(0.25) | 0.028 |
AVE 5883 (NK-1R/NK-2R antagonist) | |||||
Boot et al, 2007 | 19 | -6.40(0.12) | 19 | -6.74(0.12) | 0.004 |
CS-003 (NK-1R/NK-2R/NK-3R antagonist) | |||||
Schelfhout et al, 2006 | 15 | -5.92(0.83) | 15 | -6.99(0.66) | <0.05 |
DNK 333 (NK-1R/NK-2R antagonist) | |||||
Joos et al, 2004 | 18 | -5.60* | 18 | -6.8* | <0.001 |
SR 48068 (NK-2R antagonist) | |||||
Schoor et al, 1998 | 12 | -7.02(0.28) | 12 | -7.64(0.19) | 0.05 |
• LUNG FUNCTION: | |||||
FEV 1 (% fall) | |||||
AVE 5883 (NK-1R/NK-2R antagonist) | |||||
Boot e tal, 2007 | 19 | 145.5(11.7) | 19 | 116.2(11.7) | 0.01 |
SR 48968C (NK-1R/NK2R antagonist) | |||||
Kraan e tal, 2001 | 12 | 81(4) | 6 | 78(3) | n.s. |
FEV 1 (L) | |||||
CS-003 (NK-1R/NK-2R/NK-3R antagonist) | |||||
Schelfhout e tal, 2006 | 15 | 3.34(0.62) | 15 | 3.25(0.71) | n.s. |
FK224 (NK-1R/NK-2R antagonist) | |||||
Joos e tal, 1996 | 10 | 3.66 × 10-3(0.25) | 10 | 3.67 × 10-3 (0.21) | n.s. |
• AIRWAY INFLAMMATION: | |||||
Eosinophils % | |||||
AVE 5883 (NK-1R/NK-2R antagonist) | |||||
Boot e tal, 2007 | 19 | 4.86(1.75) | 19 | 3.33(1.58) | n.s. |
eNO ppb | |||||
AVE 5883 (NK-1R/NK-2R antagonist) | |||||
Boot e tal, 2007 | 19 | 37.64(6.40) | 19 | 43.44(6.57) | 0.32 |